LISTED Mainboard NSE & BSE Pharmaceuticals 📍 Rajkot, Gujarat, India Live

Anlon Healthcare Limited IPO

Pharmaceuticals / Chemical Manufacturing · ISIN: INE0Y8W01025 · Registrar: KFin Technologies Limited

Price Band ₹86 – ₹91

Issue Size ₹121.03 Cr

Lot Size 164 shares

Grey Market Premium —

Subscription (Total) 7.12x

Last updated 1 week ago · refreshes automatically

🔎 Check Allotment Status

More Pharmaceuticals IPOs → More IPOs from Rajkot →

📅 IPO Timeline

DRHP Filed

20 Feb 2025

RHP Filed

20 Aug 2025

Anchor Investors

25 Aug 2025

IPO Opens

26 Aug 2025

IPO Closes

29 Aug 2025

Allotment

01 Sep 2025

Refund

02 Sep 2025

Shares Credit

02 Sep 2025

Listing

03 Sep 2025

📈 Grey Market Premium Trend

Latest GMP: ₹2

📊 Subscription Status

Retail

47.26x

QIB

1.07x

NII

10.61x

Total Subscription 7.12x

As of 2025-08-29 17:00

Day	Retail	QIB	NII	Total
Day 1	8.99x	0.91x	0.71x	1.69x
Day 2	22.33x	1.01x	2.09x	3.30x
Day 3	47.26x	1.07x	10.61x	7.12x

📋 IPO Details

Open Date26 Aug 2025

Close Date29 Aug 2025

Allotment Date01 Sep 2025

Listing Date03 Sep 2025

Price Band₹86 – ₹91

Lot Size164

Face Value₹10 Per Share

Total Issue Size₹121.03 Cr

Fresh Issue₹121.03 Cr

Offer For Sale₹0 Cr

Minimum Investment₹14,924

Max Retail Investment₹194,012

Employee Discount0

Retail Reservation10%

QIB Reservation75%

NII Reservation15%

Total Shares Offered13,300,000 shares

QIB Shares3,990,000

NII Shares1,995,000

Retail Shares1,330,000

Min Lot — sNII2296 shares

Min Lot — bNII11152 shares

Application ModeASBA / UPI

Lead ManagerInteractive Financial Services Limited

RegistrarKFin Technologies Limited

Listing Price₹92

Listing Gain1.1%

⚓ Anchor Investor Details

Amount Raised₹54.46 Cr

Shares Allotted5,985,000

50% Lock-in Ends01 Oct 2025

Remaining Lock-in Ends30 Nov 2025

🏢 Company Profile

Home
IPOs
Anlon Healthcare Limited IPO

Anlon Healthcare Limited is a research-driven chemical manufacturing company based in Rajkot, Gujarat, engaged in manufacturing high-purity pharmaceutical intermediates and active pharmaceutical ingredients (APIs). Its products serve pharmaceutical, nutraceutical, personal care and animal health applications, with customers in more than 15 countries.

Zepto IPO Moves Closer, Rs. 9,500 Crore Listing Plan Could Change Quick Commerce In India

HeadquartersRajkot, Gujarat

CityRajkot

Statedone

CountryIndia

Employees105

SectorPharmaceuticals

Promoter Holding (Pre-Issue)70.26%

Promoter Holding (Post-Issue)52.68%

👨‍💼 Promoters

Punitkumar R. RasadiaMeet Atulkumar VachhaniMamata Punitkumar Rasadia

🌍 Global Presence

IndiaItalyGermanySouth KoreaChinaJapanBrazilArgentinaMexicoEgyptTurkeyUKUAEChileColombia

📦 Products & Services

Pharmaceutical Intermediates: Loxoprofen Acid, N-methyl Desloratadine, Ketoprofen Ethyl Ester (KEE), 2-Phenylpropanoic Acid (2-PPA), MCP, Ethyl 1H-tetrazole-5-carboxylate and others.Active Pharmaceutical Ingredients (APIs): Loxoprofen Sodium Dihydrate, Ketoprofen, Dexketoprofen Trometamol, Ketoprofen Lysinate, Loxapine Succinate, Desloratadine, Loratadine and others.Nutraceutical APIs and ingredients for personal care and veterinary applications.

💹 Financial Highlights

Financial Year	Revenue	Profit After Tax	EBITDA
FY25	₹120.28 Cr	₹20.51 Cr	₹32.37 Cr
FY24	₹66.58 Cr	₹9.66 Cr	₹15.57 Cr
FY23	₹112.88 Cr	₹5.82 Cr	₹12.66 Cr

📊 Key Ratios

EPS6.38

ROE25.50

ROCE21.93

NAV18.03

Debt/Equity0.73

P/E23.57

✅ Company Strengths

Experienced promoters and management team.
Diverse portfolio of pharmaceutical intermediates and APIs.
In-house testing, quality control and quality assurance capabilities.
65 commercialized products, with additional products in pilot and laboratory stages.
Customers across more than 15 countries.
Products manufactured to Indian and international pharmacopeia standards.

⚠️ Risk Factors

Revenue depends on a limited number of customers.
Operations are concentrated in a single manufacturing facility in Rajkot, Gujarat.
Dependence on a limited number of raw-material suppliers concentrated in western India.
Regulatory approvals and quality requirements can affect commercialization and operations.
Pharmaceutical/API industry competition and product demand changes may affect performance.
Foreign-currency movements can affect export-related revenue and cash flows.

🎯 IPO Objectives

Funding capital expenditure requirements for proposed expansion — ₹30.72 Cr.
Full or part repayment/prepayment of certain secured borrowings — ₹5.00 Cr.
Funding working-capital requirements — ₹43.15 Cr.
General corporate purposes and issue-related expenses.

📄 Important Documents

🔎 Check Allotment Status 📥 DRHP 📥 RHP 📥 Prospectus 📥 Annual Report 📥 Investor Presentation

❓ Frequently Asked Questions

What is the Anlon Healthcare IPO price band?

₹86–₹91 per share.

What is the Anlon Healthcare IPO lot size?

164 shares.

What was the minimum investment?

₹14,924 for one lot at the upper price band.

When did the Anlon Healthcare IPO open and close?

26 August 2025 to 29 August 2025.

When was Anlon Healthcare listed?

3 September 2025 on BSE and NSE.

What was the final subscription?

7.12x overall, with QIB 1.07x, NII 10.61x and Retail 47.26x.

📰 Related News

Anlon Healthcare IPO price band fixed at ₹86–₹91 per share.
Anlon Healthcare IPO opened on 26 August 2025 and closed on 29 August 2025.
Anlon Healthcare IPO received 7.12x final subscription.
Anlon Healthcare shares listed on BSE and NSE on 3 September 2025 at ₹92.